Funding for this research was provided by:
University of Illinois Chancellor's Innovation Fund (CIF) Proof of Concept Award
Text and Data Mining valid from 2019-10-15
First Online: 15 October 2019
Compliance with Ethical Standards
: MS is CMO and shareholder of Dystrogen Therapeutics SA, the company holds a license for DEC Therapy. The author declares a potential conflict of interest. MS is the inventor on the patent application filed by University of Illinois at Chicago related to chimeric cell therapy for Duchenne muscular dystrophy (WO/2016/201182). AH is the adviser to the Dystrogen Therapeutics.
: The authors MS, MM, PL, JC, SB and AH do not have any non-financial conflict of interest.